

KEY FACTS:

OTCQB: MDFZF
 TSXV: MFS
 Current Price: \$0.03 Market Cap: \$5M
 52-Week Range: \$0.01-0.04 Shares
 Outstanding: 185M

RECENT NEWS:

Medifocus, Inc. Announces FDA PMA Supplement Approval for New Labeling for the Prolieve® Thermodilatation™ Device

The successful completion of the 5-year follow-up FDA Post Approval Study (PAS) and the approval of the PMA Supplement labeling are significant milestones and achievements to enable Medifocus to rebrand Prolieve® as the only FDA approved Transurethral ThermoDilatation™ Microwave Therapy (TUTD™) BPH treatment system with proven excellent short-term and long-term clinical benefits. Other approved key findings of the PAS include stabilization of PSA (Prostate-specific antigen) serum levels and Prostate Sizes during the entire 5 years of follow-up.

Medifocus, Inc. Submits for New Patent Titled “Thermodilatation and Thermocompression to Facilitate Targeted Cluster Tissue Ablation and Immune Response”

This Patent Pending invention will add to Medifocus' extensive patent portfolio of already issued USA and International Patents. The patent utilizes thermocompression technologies such as: Prolieve® Transurethral Thermodilatation™ (TUTD™), APA1000 Breast Cancer Focused Microwave Treatment device and/or other thermocompression technologies to entrap pre-implanted high electric conductive material to facilitate focused heating and/or activation of molecular therapeutics to cause Cluster Tissue Ablation.

Medifocus, Inc. Announces Increase in Revenue and Positive Cash Flow

Revenue increased 26% for the quarter ending September 30, 2018, and 14% for the six months ending September 30, 2018, compared to the same periods in 2017. It also recorded a \$10,151 positive cash flow from operating activities for the six months ended September 30, 2018, compared to using \$83,359 and \$389,268 cash in operating activities during the six months ended September 30, 2017 and September 30, 2016, respectively.

About Medifocus Inc.


Medifocus, Inc. (TSXV-MFS, OTC-MDFZF) is a Biotechnology Company with a portfolio of medical technologies that utilize patented Focal Thermal Technology to treat conditions ranging from Prostate Diseases to Breast Cancer.

Prolieve® Thermodilatation™ System (TUTD™) For Enlarged Prostate (BPH)

The Prolieve® Transurethral ThermoDilatation™ Therapy (TUTD™) offers a unique "Thermodilatation" treatment for BPH. Prolieve® is the only patented and FDA approved Thermodilatation device on the market. Prolieve® is a proven technology with over 100,000 cases performed in the U.S. alone. It is a combination therapy simultaneously using Focused Microwave Heating together with Pressurized Balloon Dilatation therapy. BPH is a medical condition resulting in enlargement of the prostate gland and affects over about 50% of all men over the age of 50. The unique combination treatment is a 45-minute, in-office, outpatient procedure which is performed and well-tolerated under local anesthesia. Patients do not require a post treatment foley catheter about 90% of the time in contrast to the other invasive or even minimally invasive treatment options. Additionally, the majority of patients experience significant and immediate relief of their BPH symptoms. With the recent FDA approval of Post Market Approval Supplement for new labeling, Medifocus Inc. can officially claim durable and lasting clinical benefits for at least 5 years of follow-up. Other key findings of the PAS include stabilization of PSA (Prostate-specific antigen) serum levels and prostate sizes during the entire 5 years of follow-up. It implies that the Prolieve® treatment may help prevent the natural progression of BPH and even Early Prostate Cancer for select patients.



**Prolieve Treatment Illustration
Heat + Dilation**



As the population continues to age, the prevalence of BPH, an age-related disorder, will continue to increase. The potential of the worldwide BPH treatment market is estimated to be in billions of dollars. Medifocus' strategy is to capitalize on recent positive clinical findings in the PAS by reaching out to patients and physicians through social media, direct mailing, and other media channels to showcase the benefits of Prolieve® Therapy over other BPH treatment options.

COMPLETED PHASE II RANDOMIZED STUDY RESULTS


APA Microwave Focusing Technology

The Medifocus management team has been working with researchers at Massachusetts Institute of Technology (MIT) which developed, originally for the U.S. Department of Defense, a microwave control technology known as “Adaptive Phased Array” (APA). This technology permits properly designed microwave devices to focus and concentrate energy targeted at diseased tissue areas deep within the body and to heat them selectively, without adverse impact on surrounding healthy tissue.

The APA technology’s first indication is locally advanced breast cancer (LABC), which involves large tumors generally treated first with neo-adjuvant chemotherapy to induce tumor shrinkage and then followed by either radical surgery or breast conservation surgery, depending on the final size of the tumor.

Medifocus’ focused-heat treatment can significantly improve the efficacy of neo-adjuvant chemotherapy in shrinking LABC, improving the chance of breast conservation, and decreasing the need for radical breast surgery. Focused microwaves can be used to shrink breast tumors up to 8cm in diameter, vastly improving the chance of breast conservation for these patients who under normal circumstances will have no option but to undergo radical breast surgery.

Over 1.6 million new cases of breast cancer diagnosed each year. The Company has received regulatory approvals to start the APA 1000’s pivotal Phase-III clinical trials. The Company’s goal is to improve outcomes and standards of care in cancer treatment.



Evaluation Population 24pts


T2, T3 tumors > 2 cm at enrollment

Thermochemo: 88.4% (Median)


Chemo Alone: 58.8% (Median)

P=0.048

To detect and destroy an enemy missile, microwave energy is targeted on it, simultaneously nullifying enemy jamming



To kill a cancerous tumor, microwave focused heat is targeted on the tumor while simultaneously nullifying any energy that would burn surrounding tissue



Management Team

Dr. William W. Jow, M.D. (President, CEO) received his M.D. degree from New York University in 1986. He completed his Urology Fellowships at Weill Cornell Medical College and Rockefeller University Center for Biomedical Research in 1993. He then served as Assistant Professor at Rutgers Robert Wood Johnson Medical School. Dr. Jow has been a practicing urologist for over 30 years, and was Chairman of Urology at Hackensack Meridian Health –Bayshore Medical Center in New Jersey from 2013 to 2017. He joined Medifocus as its Medical Director since November 2014 and became its President in March 2016 and CEO since October 2016.

Mr. Mirsad Jakubovic (CFO) is a Chartered Accountant. His experience includes working as the Director of Finance and Administration for Havana House Cigar and Tobacco Merchants Ltd. and as Director of Finance and Administration for Swatch Group Canada Ltd. Mr. Jakubovic received his EMBA from the Richard Ivey School of Business and his B.Comm. from the University of Toronto.

Dr. Stuart E. Katz, M.D. (V.P. of Operations and Medical Director) received his M.D. degree from Tufts University. He served as Urology Fellow at Weill Cornell Medical College, followed by Urologic Oncology Fellowship at Memorial Sloan-Kettering Cancer Center in New York City. Dr. Katz became Clinical Professor at George Washington School of Medicine and Founder & Director of Operations, Mid-Atlantic Kaiser Permanente Clinic in Washington D.C. He was also appointed Chief of Urology at the Fairfax Hospital in Virginia.

This document may contain forward-looking statements as well as information about management’s view of Medifocus’s future expectations, plans and projects, within the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks, uncertainties and other factors which may cause the results to be materially different than those expressed or implied in such statements. These risk factors and others are included from time to time in documents Medifocus files with the Securities and Exchange Commission.